TW473394B - Pharmaceutical composition comprising a smaller oral dosage form of valsartan - Google Patents

Pharmaceutical composition comprising a smaller oral dosage form of valsartan Download PDF

Info

Publication number
TW473394B
TW473394B TW086113018A TW86113018A TW473394B TW 473394 B TW473394 B TW 473394B TW 086113018 A TW086113018 A TW 086113018A TW 86113018 A TW86113018 A TW 86113018A TW 473394 B TW473394 B TW 473394B
Authority
TW
Taiwan
Prior art keywords
oral dosage
valsartan
pharmaceutical composition
dosage form
smaller oral
Prior art date
Application number
TW086113018A
Other languages
English (en)
Chinese (zh)
Inventor
Robert Frank Wagner
Yoshimitsu Katakuse
Takashi Taike
Fujiki Yamato
Manfred Kohlmeyer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW473394(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of TW473394B publication Critical patent/TW473394B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW086113018A 1996-06-27 1997-09-09 Pharmaceutical composition comprising a smaller oral dosage form of valsartan TW473394B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9613470.5A GB9613470D0 (en) 1996-06-27 1996-06-27 Small solid oral dosage form

Publications (1)

Publication Number Publication Date
TW473394B true TW473394B (en) 2002-01-21

Family

ID=10795969

Family Applications (1)

Application Number Title Priority Date Filing Date
TW086113018A TW473394B (en) 1996-06-27 1997-09-09 Pharmaceutical composition comprising a smaller oral dosage form of valsartan

Country Status (32)

Country Link
US (3) US6294197B1 (enExample)
EP (7) EP1767206B1 (enExample)
JP (5) JP2000506540A (enExample)
KR (6) KR101208430B1 (enExample)
CN (3) CN1133427C (enExample)
AR (2) AR008618A1 (enExample)
AT (3) ATE371449T1 (enExample)
BR (1) BR9709956A (enExample)
CA (2) CA2673462C (enExample)
CO (1) CO4870755A1 (enExample)
CY (1) CY2553B1 (enExample)
CZ (1) CZ296850B6 (enExample)
DE (3) DE69738089T2 (enExample)
DK (3) DK1410797T3 (enExample)
ES (3) ES2231873T3 (enExample)
GB (1) GB9613470D0 (enExample)
HU (1) HU229134B1 (enExample)
ID (1) ID17553A (enExample)
IL (2) IL127564A0 (enExample)
MY (3) MY123149A (enExample)
NO (2) NO317181B1 (enExample)
NZ (2) NZ333385A (enExample)
PE (1) PE87498A1 (enExample)
PL (2) PL188271B1 (enExample)
PT (3) PT914119E (enExample)
RU (5) RU2294743C2 (enExample)
SI (2) SI1410797T1 (enExample)
SK (1) SK285902B6 (enExample)
TR (1) TR199802698T2 (enExample)
TW (1) TW473394B (enExample)
WO (1) WO1997049394A2 (enExample)
ZA (1) ZA975673B (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US20030045561A1 (en) * 2001-02-06 2003-03-06 Smithkline Beecham Corporation Method of treating isolated systolic hypertension
SK11902000A3 (sk) * 1998-03-04 2001-02-12 Takeda Chemical Industries, Ltd. Prostriedok s predĺženým uvoľňovaním pre antagonistu angiotenzínu ii, jeho príprava a použitie
CN1195500C (zh) 1998-05-18 2005-04-06 武田药品工业株式会社 可口腔崩解的片剂
DE69936992T2 (de) * 1998-07-10 2008-03-06 Novartis Pharma Ag Bluthochdruckgegenmittelkombination des valsartan und kalziumkanal blocker
BR9916576A (pt) 1998-12-23 2001-10-02 Novartis Ag Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2
CZ20012682A3 (cs) * 1999-01-26 2001-10-17 Novartis Ag Pouľití antagonistů receptoru angiotensinu II pro léčení akutního infarktu myokardu
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
EP1872797A3 (en) * 1999-08-24 2008-04-02 Medicure International Inc. Treatment of cardiovascular and related pathologies
DE10066408B4 (de) * 2000-03-24 2010-03-18 3M Espe Dental Ag Verwendung feinkörniger Pulver für supragingivales Pulverstrahlen
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2001097805A2 (en) * 2000-06-22 2001-12-27 Novartis Ag Solid valsartan pharmaceutical compositions
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
AU2005200815B2 (en) * 2000-06-22 2008-01-17 Novartis Ag Solid valsartan pharmaceutical compositions
AU2001289672B2 (en) 2000-07-19 2005-12-08 Novartis Ag Valsartan salts
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2003013609A1 (fr) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
US7199144B2 (en) * 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
US20040242661A1 (en) * 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
TW200505879A (en) * 2003-04-21 2005-02-16 Teva Pharma Process for the preparation of valsartan
WO2004094391A2 (en) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan and intermediates thereof
KR100882156B1 (ko) * 2003-08-08 2009-02-06 아지노모토 가부시키가이샤 나테글리니드 함유 제제
WO2005041941A2 (en) * 2003-11-03 2005-05-12 Zentiva, A.S. Valsartan containing formulation
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
JP2005187793A (ja) * 2003-12-24 2005-07-14 Rohm & Haas Electronic Materials Llc 改良された接着剤
WO2005082329A2 (en) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
WO2005089720A1 (en) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Valsartan tablets and the process for the preparation thereof
US7528258B2 (en) 2004-09-02 2009-05-05 Teva Pharmaceutical Industries Ltd Preparation of olmesartan medoxomil
EP1799196B1 (en) * 2004-10-08 2016-06-22 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
US20080050605A1 (en) * 2004-10-15 2008-02-28 Rapp Knut M Pan Coating Process
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
EA012392B1 (ru) * 2004-12-24 2009-10-30 Крка, Д.Д. Ново Место Твердая фармацевтическая композиция, содержащая валсартан
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
EP1982711A1 (en) * 2005-05-31 2008-10-22 Mylan Laboratories, Inc Compositions comprsing nebivolol
WO2007005967A2 (en) * 2005-07-05 2007-01-11 Teva Pharmaceutical Industries Ltd. Process for preparing valsartan
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
US20080227836A1 (en) * 2005-10-31 2008-09-18 Lupin Ltd Stable Solid Oral Dosage Forms of Valsartan
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
EP2007385A4 (en) * 2006-03-23 2010-08-18 Sinai School Medicine CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
MX2008015621A (es) 2006-06-06 2009-03-06 Oleg Iliich Epshtein Agente medicinal para el tratamiento de obesidad, diabetes y enfermedades relacionadas con la tolerancia deteriorada de glucosa.
US20090304797A1 (en) * 2006-06-23 2009-12-10 Tarur Venkatasubramanian Radha Process for the Preparation of Micronized Valsartan
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
PE20081364A1 (es) * 2006-09-04 2008-12-04 Novartis Ag Composicion farmaceutica que comprende valsartan
JP2010508266A (ja) * 2006-10-30 2010-03-18 ハナル ファーマシューティカル カンパニー リミテッド チアジド系化合物およびアンジオテンシン−ｉｉ−受容体遮断剤を含む放出性が制御された薬学的組成物
WO2008064338A2 (en) * 2006-11-22 2008-05-29 Rubicon Research Pvt. Ltd. Valsartan formulation for pulsatile delivery
EP2139473A1 (en) * 2007-03-29 2010-01-06 Alembic Limited Valsartan tablet formulations
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
RU2471356C2 (ru) * 2007-07-31 2013-01-10 Карджилл, Инкорпорейтед Декстроза для прямого прессования
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
CN101396366B (zh) * 2007-09-25 2010-10-13 浙江华海药业股份有限公司 含缬沙坦的固体口服制剂及其制备方法
JP2010540547A (ja) * 2007-09-28 2010-12-24 ノバルティス アーゲー アリスキレンおよびバルサルタンのガレヌス製剤
RU2487710C2 (ru) * 2007-10-09 2013-07-20 Новартис Аг Фармацевтическая композиция валсартана
MY153730A (en) 2007-11-06 2015-03-13 Novartis Ag Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
US8785432B2 (en) * 2007-12-31 2014-07-22 Lupin Limited Pharmaceutical compositions of amlodipine and valsartan
CA2713581A1 (en) * 2008-02-28 2009-09-03 Novartis Ag Valsartan solid oral dosage forms and methods of making such formulations
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
US20090226516A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Sartan compositions
CN102065847A (zh) * 2008-04-29 2011-05-18 韩诺生物制约株式会社 含有血管紧张素-ⅱ受体阻断剂的药物制剂
AU2009257174A1 (en) * 2008-06-09 2009-12-17 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers
KR101033975B1 (ko) * 2008-10-10 2011-05-11 이희엽 직접압축법을 이용한 발사르탄 함유 고형 경구 제형의 제조방법 및 이에 따라 제조된 고형 경구 제형
DE102008051783A1 (de) * 2008-10-17 2010-04-22 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Valsartan enthaltende Tablette
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
WO2010104485A2 (en) 2009-03-11 2010-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
RU2398570C1 (ru) * 2009-04-17 2010-09-10 Илья Николаевич Медведев Способ снижения содержания микровезикул в крови при стабильной стенокардии напряжения i-ii функционального класса с артериальной гипертонией
WO2011027021A1 (en) * 2009-09-01 2011-03-10 Orion Corporation A method for the treatment of hypertension
KR101084783B1 (ko) * 2009-09-01 2011-11-22 삼성에스디아이 주식회사 이차 전지 및 그의 제조 방법
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CN101897675B (zh) * 2010-02-10 2012-11-21 温士顿医药股份有限公司 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
EP2536396B1 (en) 2010-02-16 2016-08-10 KRKA, D.D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
JP5882796B2 (ja) 2011-03-31 2016-03-09 キヤノン株式会社 振動体の駆動方法、振動装置、該振動装置を有する駆動装置、及び光学機器
GB201116993D0 (en) * 2011-10-03 2011-11-16 Ems Sa Pharmaceutical compositions of antihypertensives
BR112014015620A8 (pt) 2011-12-26 2017-07-04 Novartis Ag comprimidos e agentes revestidos a seco
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
WO2014038895A1 (ko) * 2012-09-06 2014-03-13 한국콜마주식회사 발사르탄 함유 고형 경구제형 및 그 제조방법
JP2014062064A (ja) * 2012-09-21 2014-04-10 Ohara Yakuhin Kogyo Kk バルサルタン含有錠剤の製造方法
JP6238831B2 (ja) * 2014-04-25 2017-11-29 沢井製薬株式会社 バルサルタン含有錠剤及びその製造方法
JP6141472B2 (ja) * 2016-03-02 2017-06-07 大原薬品工業株式会社 バルサルタン含有錠剤の製造方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CA3103599A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200039A (en) 1962-05-28 1965-08-10 Pfizer & Co C Non-granulated tablets with 20% sorbitol in a particle size of from about 100mu to about 2000mu
GB1422176A (en) 1973-05-05 1976-01-21 Beecham Group Ltd Pharmaceutical tablets
AU528098B2 (en) 1978-11-16 1983-04-14 Beecham Group Plc Analgesic tablet
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
US4238485A (en) * 1979-10-29 1980-12-09 Merck & Co., Inc. Novel pharmaceutical compositions
EP0070127A3 (en) 1981-07-10 1983-08-17 Beecham Group Plc Tablets
US4543359A (en) * 1982-10-01 1985-09-24 Eaton Laboratories, Inc. Treating cardiac arrhythmias with dantrolene sodium
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4743612A (en) * 1986-10-17 1988-05-10 Berlex Laboratories, Inc. Prodrug derivatives of the cardiotonic agent 4-ethyl-1,3-dihydro-5-(4-(2-methyl-1H-imidazol-1-yl)benzoyl)-2H-imidazol-2-one, composition containing them, and method of using them to treat cardiac failure
DE3705055A1 (de) * 1987-02-18 1988-09-01 Boehringer Ingelheim Kg Verwendung von 2-(3-fluor-4-methylphenylimino)-imidazolidin zur behandlung der koronaren herzkrankheit
JP2518854B2 (ja) * 1987-06-19 1996-07-31 旭化成工業株式会社 固形製剤の製法
DE3739779A1 (de) * 1987-11-24 1989-06-08 Beiersdorf Ag Pharmazeutische praeparate
SE506179C2 (sv) * 1989-01-23 1997-11-17 Ciba Geigy Ag Farmaceutisk lågkomposition av benazepril och ett tiaziddiuretikum
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
IL97219A (en) 1990-02-19 1995-12-08 Ciba Geigy Ag Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
JPH06501475A (ja) * 1990-09-28 1994-02-17 メルク　エンド　カンパニー　インコーポレーテッド イブプロフェン−利尿剤の組み合わせ
DE69331839T2 (de) * 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
ZA931063B (en) 1992-02-17 1993-09-23 Ciba Geigy Treatment of glaucoma.
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
WO1994009778A1 (en) 1992-10-26 1994-05-11 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
AU5745394A (en) 1992-12-30 1994-08-15 Fmc Corporation Readily available konjac glucomannan sustained release excipient
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
US5464854A (en) 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
AT401871B (de) * 1994-01-28 1996-12-27 Gebro Broschek Gmbh Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
JP3534130B2 (ja) * 1994-03-01 2004-06-07 旭化成ケミカルズ株式会社 医薬品組成物
GB9404010D0 (en) * 1994-03-02 1994-04-20 Opt Tel Services Limited Telephone dialling monitoring and route selecting apparatus
PL316259A1 (en) * 1994-03-17 1997-01-06 Ciba Geigy Ag Treatment of diabetic nephropathy with valsartan
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE19502065C2 (de) * 1995-01-14 1996-05-02 Prophyta Biolog Pflanzenschutz Pilzisolat mit fungizider Wirkung
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
FR2735365B1 (fr) * 1995-06-14 1997-09-05 Sanofi Sa Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
JP2011123241A (ja) * 2009-12-10 2011-06-23 Canon Inc 撮影システム

Also Published As

Publication number Publication date
WO1997049394A2 (en) 1997-12-31
US20030035832A1 (en) 2003-02-20
CA2259148C (en) 2009-09-29
US6294197B1 (en) 2001-09-25
EP1767206A3 (en) 2007-04-18
TR199802698T2 (xx) 1999-04-21
ATE276750T1 (de) 2004-10-15
DE69739642D1 (de) 2009-12-10
DK1410797T3 (da) 2007-10-15
NO986056D0 (no) 1998-12-22
ATE371449T1 (de) 2007-09-15
DE69738089D1 (de) 2007-10-11
PL188233B1 (pl) 2004-12-31
DK0914119T3 (da) 2005-01-31
EP1767206A2 (en) 2007-03-28
RU2453306C2 (ru) 2012-06-20
DE69730834T2 (de) 2005-10-06
RU2013113610A (ru) 2014-10-10
HK1060700A1 (en) 2004-08-20
HK1019858A1 (en) 2000-06-09
ZA975673B (en) 1997-12-29
EP0914119A3 (en) 2002-03-06
KR20060079260A (ko) 2006-07-05
AR059324A2 (es) 2008-03-26
RU2294743C2 (ru) 2007-03-10
RU2007100200A (ru) 2008-07-20
PE87498A1 (es) 1998-12-21
EP1776953A1 (en) 2007-04-25
PT1767206E (pt) 2010-01-27
PL188271B1 (pl) 2005-01-31
JP2012051948A (ja) 2012-03-15
EP1410797A1 (en) 2004-04-21
JP4969338B2 (ja) 2012-07-04
NO317181B1 (no) 2004-09-06
SK285902B6 (sk) 2007-10-04
CN1475207A (zh) 2004-02-18
CA2673462A1 (en) 1997-12-31
HUP0203374A3 (en) 2004-06-28
DE69730834D1 (de) 2004-10-28
PL330709A1 (en) 1999-05-24
AU3340297A (en) 1998-01-14
KR20110063587A (ko) 2011-06-10
EP1767206B1 (en) 2009-10-28
CZ426998A3 (cs) 1999-03-17
HU229134B1 (en) 2013-08-28
HUP0203374A2 (hu) 2004-05-28
SK178498A3 (en) 1999-06-11
EP0914119B1 (en) 2004-09-22
RU2203054C2 (ru) 2003-04-27
MY123149A (en) 2006-05-31
PT914119E (pt) 2005-02-28
ID17553A (id) 1998-01-08
IL127564A0 (en) 1999-10-28
AU724998B2 (en) 2000-10-05
CO4870755A1 (es) 1999-12-27
MY146868A (en) 2012-09-28
KR101161283B1 (ko) 2012-07-02
JP2003231634A (ja) 2003-08-19
EP1410797B1 (en) 2007-08-29
CN1951372A (zh) 2007-04-25
EP1767207A2 (en) 2007-03-28
IL195339A0 (en) 2009-08-03
KR100618038B1 (ko) 2006-11-30
CN1951372B (zh) 2011-03-23
EP1767207A3 (en) 2007-04-18
SI0914119T1 (en) 2005-04-30
US6485745B1 (en) 2002-11-26
CN1133427C (zh) 2004-01-07
KR20080014149A (ko) 2008-02-13
SI1410797T1 (sl) 2008-08-31
BR9709956A (pt) 1999-08-10
PT1410797E (pt) 2007-12-03
NO20041287L (no) 2004-03-26
NO986056L (no) 1998-12-22
NO331739B1 (no) 2012-03-12
JP2007238637A (ja) 2007-09-20
EP0914119A2 (en) 1999-05-12
CN1475207B (zh) 2010-09-29
ES2290400T3 (es) 2008-02-16
MY156312A (en) 2016-01-29
KR20050092054A (ko) 2005-09-16
DE69738089T2 (de) 2008-05-21
JP2000506540A (ja) 2000-05-30
CA2673462C (en) 2011-10-04
ATE446749T1 (de) 2009-11-15
CY2553B1 (en) 2008-07-02
US6858228B2 (en) 2005-02-22
GB9613470D0 (en) 1996-08-28
ES2335683T3 (es) 2010-03-31
KR101208430B1 (ko) 2012-12-05
NZ333385A (en) 2000-09-29
CN1232394A (zh) 1999-10-20
NZ524346A (en) 2004-09-24
KR100792389B1 (ko) 2008-01-08
DK1767206T3 (da) 2010-01-25
CA2259148A1 (en) 1997-12-31
JP2014012747A (ja) 2014-01-23
WO1997049394A3 (en) 2001-12-20
AR008618A1 (es) 2000-02-09
KR20090099020A (ko) 2009-09-18
KR20000022111A (ko) 2000-04-25
ES2231873T3 (es) 2005-05-16
EP2055301A1 (en) 2009-05-06
CZ296850B6 (cs) 2006-07-12
EP1774967A1 (en) 2007-04-18
RU2009115778A (ru) 2010-11-10

Similar Documents

Publication Publication Date Title
TW473394B (en) Pharmaceutical composition comprising a smaller oral dosage form of valsartan
IL190801A0 (en) Therapeutic combination of amlodipine and benazepril/benazeprilat
EA200702187A1 (ru) Композиция таблетки прамипексола с замедленным высвобождением
MXPA04005105A (es) Formulaciones de acitromicina directamente compresibles.
IT1256282B (it) Composizione farmaceutica che comprende una particolare forma fisica di un derivato di un'ammide eterociclica
ATE333265T1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
CY1116770T1 (el) Συνδυασμενη χρηση βαλσαρτανης και παρεμποδιστων διαυλων ασβεστιου για θεραπευτικους σκοπους
JP2003530346A5 (enExample)
DE50109662D1 (de) Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DZ3358A1 (fr) Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression
RU2002123182A (ru) Содержащая ибупрофен композиция
EP2277519A3 (en) Use of Angiotensin II type 1 receptor antagonists for the prevention of stroke, diabetes and/or congestive heart failure
CA2411882A1 (en) Solid valsartan pharmaceutical compositions
AU2006249254A1 (en) Combinations comprising COX-2 inhibitors and aspirin
CA2378988A1 (fr) Composition pharmaceutique flottante comprenant une phase active et une phase non active
NO974400L (no) Kombinasjonspreparater inneholdende benazepril eller benazeprilat og valsartan
JP2001522794A5 (enExample)
WO2002007716A3 (en) Method for treating angina
JP2004527489A5 (enExample)
BR0111102A (pt) Uso de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4pip eridinometanol ou sua pró-droga no tratamento de sintomas de demência e psicose induzida por dopamina
HK1079984A1 (zh) 抑制hiv复制的甘氨酰胺衍生物
JP2005528398A5 (enExample)
TNSN07166A1 (en) Composition comprising vlp and amyloid-beta peptide
CO5700697A2 (es) Forma de dosis solida
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MK4A Expiration of patent term of an invention patent